Ascendis Pharma A/S Cost Of Sales
Ascendis Pharma A/S (ASND) reported Cost Of Sales of EUR 94.92 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-02-11.
Financial Statements › Expense Statement
ifrs-full:CostOfSales · last filed 2026-02-11
- Ascendis Pharma A/S cost of sales for the quarter ending 2025-12-31 was 23.60M EUR, a 68.28% increase year-over-year.
- Ascendis Pharma A/S cost of sales for the quarter ending 2025-09-30 was 22.35M EUR, a 99.57% increase year-over-year.
- Ascendis Pharma A/S cost of sales for the quarter ending 2025-06-30 was 31.45M EUR, a 174.29% increase year-over-year.
- Ascendis Pharma A/S cost of sales for the quarter ending 2025-03-31 was 17.52M EUR, a 131.43% increase year-over-year.
| Period end | Cost Of Sales 3 month | Cost Of Sales 6 month | Cost Of Sales 9 month | Cost Of Sales 12 month |
|---|---|---|---|---|
| 2025-12-31 | 23.60M EUR derived: 20-F 12 month − 6-K 9 month · filed 2026-02-11 | 45.95M EUR derived: sum of 2 quarters · filed 2026-02-11 | 77.40M EUR derived: sum of 3 quarters · filed 2026-02-11 | 94.92M EUR 20-F · filed 2026-02-11 |
| 2025-09-30 | 22.35M EUR 6-K · filed 2025-11-12 | 53.80M EUR derived: sum of 2 quarters · filed 2025-11-12 | 71.32M EUR 6-K · filed 2025-11-12 | 85.34M EUR derived: sum of 4 quarters · filed 2026-02-11 |
| 2025-06-30 | 31.45M EUR 6-K · filed 2025-08-07 | 48.96M EUR 6-K · filed 2025-08-07 | 62.99M EUR derived: sum of 3 quarters · filed 2026-02-11 | 74.19M EUR derived: sum of 4 quarters · filed 2026-02-11 |
| 2025-03-31 | 17.52M EUR 6-K · filed 2025-05-01 | 31.54M EUR derived: sum of 2 quarters · filed 2026-02-11 | 42.74M EUR derived: sum of 3 quarters · filed 2026-02-11 | 54.21M EUR derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-12-31 | 14.02M EUR derived: 20-F 12 month − 6-K 9 month · filed 2026-02-11 | 25.22M EUR derived: sum of 2 quarters · filed 2026-02-11 | 36.69M EUR derived: sum of 3 quarters · filed 2026-02-11 | 44.26M EUR 20-F · filed 2026-02-11 |
| 2024-09-30 | 11.20M EUR 6-K · filed 2025-11-12 | 22.67M EUR derived: sum of 2 quarters · filed 2025-11-12 | 30.23M EUR 6-K · filed 2025-11-12 | 49.69M EUR derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | 11.46M EUR 6-K · filed 2025-08-07 | 19.03M EUR 6-K · filed 2025-08-07 | 38.49M EUR derived: sum of 3 quarters · filed 2026-02-11 | 45.88M EUR derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | 7.57M EUR 6-K · filed 2025-05-01 | 27.03M EUR derived: sum of 2 quarters · filed 2026-02-11 | 34.41M EUR derived: sum of 3 quarters · filed 2026-02-11 | 47.34M EUR derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | 19.46M EUR derived: 20-F 12 month − 6-K 9 month · filed 2026-02-11 | 26.84M EUR derived: sum of 2 quarters · filed 2026-02-11 | 39.77M EUR derived: sum of 3 quarters · filed 2026-02-11 | 44.40M EUR 20-F · filed 2026-02-11 |
| 2023-09-30 | 7.39M EUR 6-K · filed 2024-11-14 | 20.32M EUR derived: sum of 2 quarters · filed 2024-11-14 | 24.94M EUR 6-K · filed 2024-11-14 | 30.05M EUR derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | 12.93M EUR 6-K · filed 2024-09-03 | 17.55M EUR 6-K · filed 2024-09-03 | 22.66M EUR derived: sum of 3 quarters · filed 2025-02-12 | 24.36M EUR derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | 4.62M EUR 6-K · filed 2024-05-02 | 9.73M EUR derived: sum of 2 quarters · filed 2025-02-12 | 11.43M EUR derived: sum of 3 quarters · filed 2025-02-12 | 12.51M EUR derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | 5.11M EUR derived: 20-F 12 month − 6-K 9 month · filed 2025-02-12 | 6.80M EUR derived: sum of 2 quarters · filed 2025-02-12 | 7.89M EUR derived: sum of 3 quarters · filed 2025-02-12 | 12.14M EUR 20-F · filed 2025-02-12 |
| 2022-09-30 | 1.69M EUR 6-K · filed 2023-11-07 | 2.78M EUR derived: sum of 2 quarters · filed 2023-11-07 | 7.03M EUR 6-K · filed 2023-11-07 | 10.55M EUR derived: sum of 4 quarters · filed 2024-02-07 |
| 2022-06-30 | 1.09M EUR 6-K · filed 2023-09-05 | 5.33M EUR 6-K · filed 2023-09-05 | 8.86M EUR derived: sum of 3 quarters · filed 2024-02-07 | 8.86M EUR derived: sum of 4 quarters · filed 2024-02-07 |
| 2022-03-31 | 4.25M EUR 6-K · filed 2023-04-27 | 7.77M EUR derived: sum of 2 quarters · filed 2024-02-07 | 7.77M EUR derived: sum of 3 quarters · filed 2024-02-07 | 7.77M EUR derived: sum of 4 quarters · filed 2024-02-07 |
| 2021-12-31 | 3.52M EUR derived: 20-F 12 month − 6-K 9 month · filed 2024-02-07 | 3.52M EUR derived: sum of 2 quarters · filed 2024-02-07 | 3.52M EUR derived: sum of 3 quarters · filed 2024-02-07 | 3.52M EUR 20-F · filed 2024-02-07 |
| 2021-09-30 | 0.00 EUR 6-K · filed 2022-11-02 | 0.00 EUR derived: sum of 2 quarters · filed 2022-11-02 | 0.00 EUR 6-K · filed 2022-11-02 | |
| 2021-06-30 | 0.00 EUR 6-K · filed 2022-08-10 | 0.00 EUR 6-K · filed 2022-08-10 | ||
| 2021-03-31 | 0.00 EUR 6-K · filed 2022-05-11 | |||
| 2020-12-31 | 0.00 EUR 20-F · filed 2023-02-16 | |||
| 2019-12-31 | 0.00 EUR 20-F · filed 2022-03-02 |